AR071990A1 - Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto - Google Patents

Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto

Info

Publication number
AR071990A1
AR071990A1 ARP090101981A ARP090101981A AR071990A1 AR 071990 A1 AR071990 A1 AR 071990A1 AR P090101981 A ARP090101981 A AR P090101981A AR P090101981 A ARP090101981 A AR P090101981A AR 071990 A1 AR071990 A1 AR 071990A1
Authority
AR
Argentina
Prior art keywords
compound
lispro
insulin
hypoglycemia
diabetes
Prior art date
Application number
ARP090101981A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41110836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR071990(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR071990A1 publication Critical patent/AR071990A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compuesto de insulina lispro PEGilada que es de la formula: P-[(A)-(B)], o una sal del mismo farmaceuticamente aceptable, donde: A es la cadena A de insulina lispro (SEC ID Nø:1); B es la cadena B de insulina lispro (SEC ID Nø:3); y P es un PEG que tiene un peso molecular en el intervalo desde aproximadamente 20 kDa hasta aproximadamente 40 kDa, y en donde A y B son apropiadamente reticulados y P est  unido v¡a un enlace covalente de uretano o tioeter al grupo alfa-amino de la glicina en la posicion 1 de A, el grupo alfa-amino de la fenilalanina en la posicion 1 de B, o el grupo epsilon-amino de la lisina en la posicion 28 de B. Son altamente solubles a pH fisiologico, tienen una duracion de accion extendida, y relaciones pico-canal de menos de 2. Uso de dicho compuesto para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes. Composicion farmaceutica que lo comprende. Proceso para elaborar dicho compuesto.
ARP090101981A 2008-06-13 2009-06-02 Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto AR071990A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6128108P 2008-06-13 2008-06-13
US12139408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
AR071990A1 true AR071990A1 (es) 2010-07-28

Family

ID=41110836

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101981A AR071990A1 (es) 2008-06-13 2009-06-02 Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto

Country Status (33)

Country Link
US (3) US20110105392A1 (es)
EP (2) EP2476430B1 (es)
JP (2) JP4890662B2 (es)
KR (1) KR101238979B1 (es)
CN (1) CN102065884B (es)
AR (1) AR071990A1 (es)
AT (1) ATE554786T1 (es)
AU (1) AU2009257597B2 (es)
BR (1) BRPI0915838A2 (es)
CA (1) CA2727825C (es)
CL (1) CL2009001340A1 (es)
CO (1) CO6331292A2 (es)
CY (2) CY1112977T1 (es)
DK (2) DK2288375T3 (es)
DO (1) DOP2010000379A (es)
EA (1) EA028657B1 (es)
EC (1) ECSP10010677A (es)
ES (2) ES2473580T3 (es)
HR (2) HRP20120397T1 (es)
IL (1) IL209265A (es)
JO (1) JO2932B1 (es)
MA (1) MA32394B1 (es)
MX (1) MX2010013837A (es)
MY (1) MY158890A (es)
NZ (1) NZ588997A (es)
PE (2) PE20140974A1 (es)
PL (2) PL2288375T3 (es)
PT (2) PT2288375E (es)
RS (1) RS52361B (es)
SI (2) SI2288375T1 (es)
TW (1) TWI451876B (es)
WO (1) WO2009152128A1 (es)
ZA (1) ZA201008174B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101159559B1 (ko) * 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
CA2738615A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
EP3202394A1 (de) 2009-07-06 2017-08-09 Sanofi-Aventis Deutschland GmbH Wässrige insulinzubereitungen enthaltend methionin
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
PT2554183T (pt) 2009-11-13 2018-07-09 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1 y metionina
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2569002B1 (en) * 2010-05-10 2016-10-26 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
WO2011146574A1 (en) * 2010-05-18 2011-11-24 Neumedicines, Inc. Il-12 formulations for enhancing hematopoiesis
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX2012013586A (es) * 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
KR20200028498A (ko) 2010-06-24 2020-03-16 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2821411C (en) 2010-12-13 2020-02-25 Quiapeg Pharmaceuticals Ab Functionalized polymers
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
CN102675452B (zh) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103747806A (zh) * 2011-06-02 2014-04-23 韩美科学株式会社 非肽基聚合物-胰岛素多聚体和生产其的方法
CN105797140B (zh) * 2011-06-17 2020-08-11 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
DK2741765T3 (en) * 2011-08-10 2016-06-13 Adocia Injectable solution of at least one type of basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AR090843A1 (es) 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
AU2013276219B2 (en) 2012-06-12 2018-03-08 Quiapeg Pharmaceuticals Ab Conjugates of biologically active molecules to functionalized polymers
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
MY170671A (en) 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
KR20150082640A (ko) * 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
WO2014099577A1 (en) * 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
DK2983697T3 (en) 2013-04-03 2019-02-25 Sanofi Sa TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
SI3057984T1 (sl) 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
CN105092490B (zh) * 2014-05-04 2019-08-09 重庆派金生物科技有限公司 人胰岛素及类似物或偶联物体外生物活性测定方法
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
AR107560A1 (es) 2016-02-24 2018-05-09 Lilly Co Eli Compuesto que disminuye la glucosa en la sangre
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
WO2018153506A1 (en) * 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt
AU2018231832A1 (en) 2017-03-10 2019-08-08 Quiapeg Pharmaceuticals Ab Releasable conjugates
WO2018222787A1 (en) * 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
AU2018326799A1 (en) 2017-08-31 2020-02-27 Modernatx, Inc. Methods of making lipid nanoparticles
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
FR3084585B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
WO2021119607A1 (en) * 2019-12-13 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University Stable monomeric insulin formulations enabled by supramolecular pegylation of insulin analogues
CN113801236A (zh) * 2020-06-11 2021-12-17 宁波鲲鹏生物科技有限公司 一种赖脯胰岛素的制备方法
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
WO1988006599A1 (en) 1987-02-25 1988-09-07 Novo Industri A/S Novel insulin derivatives
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
PT1121144E (pt) * 1998-10-16 2002-11-29 Novo Nordisk As Preparados de insulina concentrada estavel para administracao pulmonar
AU2001220765A1 (en) * 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
HUP0400442A2 (hu) * 2001-05-21 2005-03-29 Nektar Therapeutics Kémiailag módosított inzulin pulmonáris beadása és eljárás az előállítására
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
BRPI0409322B8 (pt) 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
PL1789434T3 (pl) * 2004-08-31 2014-07-31 Novo Nordisk As Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
US20060045866A1 (en) 2004-09-01 2006-03-02 Chris Chappelow Novel high purity and high molecular weight mPEG alcohol compositions
US7199193B2 (en) 2004-09-28 2007-04-03 Dow Global Technologies, Inc. Polyethylene glycol compounds and process of making
EP1845105A4 (en) * 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical MODIFIED EXENDINES AND CORRESPONDING USES
US20090036353A1 (en) 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
US7824919B2 (en) 2005-03-04 2010-11-02 Dr. Reddy's Laboratories Limited Method for analyzing activated polyethylene glycol compounds
WO2006097521A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
KR101011081B1 (ko) * 2005-05-13 2011-01-25 일라이 릴리 앤드 캄파니 Ｐｅｇ화된 ｇｌｐ-1 화합물
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
EP2049149B1 (en) * 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
WO2008084051A1 (en) 2007-01-12 2008-07-17 Novo Nordisk A/S Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物

Also Published As

Publication number Publication date
KR20110017879A (ko) 2011-02-22
JP2012092124A (ja) 2012-05-17
IL209265A (en) 2014-08-31
EP2288375B1 (en) 2012-04-25
CA2727825A1 (en) 2009-12-17
HK1170659A1 (en) 2013-03-08
CY1115354T1 (el) 2017-01-04
ECSP10010677A (es) 2011-01-31
SI2476430T1 (sl) 2014-07-31
CN102065884B (zh) 2014-11-05
HRP20140480T1 (hr) 2014-07-04
JO2932B1 (en) 2015-09-15
AU2009257597B2 (en) 2011-10-06
ES2473580T3 (es) 2014-07-07
EP2476430B1 (en) 2014-05-14
US20150297681A1 (en) 2015-10-22
US9050371B2 (en) 2015-06-09
WO2009152128A1 (en) 2009-12-17
CN102065884A (zh) 2011-05-18
TWI451876B (zh) 2014-09-11
TW201010728A (en) 2010-03-16
ES2383496T3 (es) 2012-06-21
DK2476430T3 (da) 2014-06-02
CL2009001340A1 (es) 2010-06-04
NZ588997A (en) 2012-03-30
MY158890A (en) 2016-11-30
PE20140974A1 (es) 2014-08-25
ATE554786T1 (de) 2012-05-15
PT2476430E (pt) 2014-07-25
CY1112977T1 (el) 2016-04-13
DOP2010000379A (es) 2011-03-31
EA028657B1 (ru) 2017-12-29
US20110105392A1 (en) 2011-05-05
CO6331292A2 (es) 2011-10-20
EP2288375A1 (en) 2011-03-02
HK1149713A1 (en) 2011-10-14
SI2288375T1 (sl) 2012-07-31
HRP20120397T1 (hr) 2012-06-30
ZA201008174B (en) 2012-04-25
US20090312236A1 (en) 2009-12-17
AU2009257597A8 (en) 2011-01-06
JP5336572B2 (ja) 2013-11-06
CA2727825C (en) 2014-10-21
JP4890662B2 (ja) 2012-03-07
EP2476430A1 (en) 2012-07-18
JP2011524357A (ja) 2011-09-01
PT2288375E (pt) 2012-05-17
IL209265A0 (en) 2011-01-31
AU2009257597A1 (en) 2009-12-17
MA32394B1 (fr) 2011-06-01
RS52361B (sr) 2012-12-31
KR101238979B1 (ko) 2013-03-05
BRPI0915838A2 (pt) 2015-11-03
EA201170020A1 (ru) 2011-10-31
DK2288375T3 (da) 2012-05-21
PE20091960A1 (es) 2010-01-15
PL2476430T3 (pl) 2014-09-30
PL2288375T3 (pl) 2012-09-28
MX2010013837A (es) 2011-05-03

Similar Documents

Publication Publication Date Title
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
AU2012261869B2 (en) Long-acting GLP-1/Glucagon receptor agonists
JP2017206561A (ja) 長期間作用性ペプチド類似体のための組成物
RU2451029C2 (ru) Производное инсулина
KR101759499B1 (ko) 지속형 인슐린 조성물
ES2674581T3 (es) Análogo de exendina-4 pegilado con polietilenglicol o derivado del mismo, método de preparación del mismo y composición farmacéutica para evitar o tratar diabetes, que contiene el mismo como principio activo
US12391733B2 (en) Stapled intracellular-targeting antimicrobial peptides to treat infection
CA2846598C (en) Treatment of degenerative joint disease
AR089506A1 (es) Un conjugado de glp-2 especifico del sitio que emplea un fragmento de inmunoglobulina
WO2009075859A3 (en) Formulation of insulinotropic peptide conjugates
TW201833131A (zh) 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
RS61107B1 (sr) Glukagon i glp-1 ko-agonist jedinjenja
RU2009129961A (ru) АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
JP2011526886A5 (es)
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
JP2014520798A5 (es)
AU2012296951A1 (en) Protein carrier-linked prodrugs
BRPI1014416B1 (pt) Nova variante de exendina e conjugado desta
AR081042A1 (es) Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g
CA2846209A1 (en) Systemic sustained release formulation comprising elastin­like peptide repeating sequence and protein active agent
RU2013120135A (ru) Глюкозозависимые инсулинотропные пептидные аналоги
JP7544838B2 (ja) 選択的ｇｉｐ受容体アゴニストとしてのペプチド
AU2022339059A1 (en) New peptides as potent and selective gip receptor agonists
WO2015148831A1 (en) Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide
EP3468610A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same

Legal Events

Date Code Title Description
FB Suspension of granting procedure